Abstract: 1-Substituted-spiro[chroman-4,4'-imidazolidine]-2',5'-dione compounds are useful for treating arrhythmia.

Abstract: Substituted spiro[oxazolidine-5,2'-adamantane] compounds are described.

Abstract: Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, 1-mercapto C.sub.2-7 alkyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl)NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.

Abstract: Spiro-oxazolidones, -thiazolidones and -imidazolidones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic complications are also disclosed.

Abstract: The invention provides novel spiro[oxazolidine-5,3'-indoline]-2,2',4-triones of formula I bearing substituted benzyl or cinnamyl on the indoline nitrogen, together with salts and non-toxic, biodegradable precursors thereof. The compounds are potent inhibitors of the enzyme aldose reductase and are useful in treating or preventing certain diabetic complications. The invention also provides pharmaceutical compositions containing, and processes for the manufacture of, the compounds of formula I and their salts and derivatives.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2, which may be identical to or different from each other, are each independently hydrogen, straight or branched alkyl of 1 to 8 carbon atoms or arylmethyl; orR.sub.1 and R.sub.2, together with each other, are --(CH.sub.2).sub.4 or --(CH.sub.2).sub.5 --; andR.sub.3 and R.sub.4, which may be identical to or different from each other, are each independently hydrogen, straight or branched alkyl of 1 to 4 carbon atoms or arylmethyl; orR.sub.3 and R.sub.4, together with each other, are --CH.sub.3 -- or --CH.sub.2 --CH.sub.2 --;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful for the treatment of cardiovascular diseases, especially hypertension.

Abstract: Compounds of the formula I ##STR1## wherein R.sub.1 is ##STR2## wherein R.sup.I and R.sup.II each independently is alkyl of 1-4 carbon atoms, or R.sup.I and R.sup.II together with the connecting N-atom form a 5- or 6-membered heterocyclic ring whose remaining atoms are all C-atoms, or which also includes and additional N-atom, an additional O or S atom or a combination thereof; ##STR3## wherein R.sup.I and R.sup.II are as defined above; --SR.sup.III, wherein R.sup.III is methyl, ethyl or phenyl; or--OR.sup.IV, wherein R.sup.IV is methyl, ethyl, propyl, methoxymethyl, allyl, or .beta.-dimethylaminoethyl;R.sub.2 is hydrogen, methyl, or ethyl; ##STR4## wherein the wavy lines mean that the substituent is in the .alpha.- or .beta.-position, and ##STR5## M is Na, K or Li; and R.sup.V, R.sup.VI, R.sup.VII and R.sup.VIII each independently is alkyl of 1-4 carbon atoms, have valuable pharmacological properties, e.g., a combination of antiprogestational and antimineralocorticordal effects.

Abstract: Compounds of formula (I): ##STR1## a pharmaceutically acceptable salt or solvate thereof having anti-hypertensive activity, a process for their preparation and their use as pharmaceuticals.

Abstract: Azlactone-functional compounds, which are liquid above 20.degree. C., and their method of preparation from alkenyl azlactones and nucleophilic group-substituted compounds are disclosed. The azlactone-functional compounds of the invention cure in the presence of nucleophilic chain-extending or crosslinking agents to form linear or crosslinked polyamide resin systems.

Abstract: The invention relates to cyclic sulphenamides of Formula I and methods for their manufacture. Also included in the invention are compositions containing said cyclic sulphenamides and methods for the use of said compounds and compositions as lipoxygenase inhibitors.

Abstract: A process comprising reacting a 2-methyloxazoline with a 3-methyl-2-buten-1-yl derivative of the formula ##STR1## in which X is halide, sulphonate or phosphate thereby to produce a 2-methyl-3-(3-methyl-2-butenyl)-2-oxazolinium salt of the formula ##STR2## reacting the oxazolinium salt with an alcoholate of the formulaR.sup.5 --O--M (V)in which M is one equivalent of an alkali metal or alkaline earth metal cation, to produce an oxazolidine of the formula ##STR3## pyrolyzing the oxazolidine to produce a 2-methyl-3-(3-methyl-2-butenyl)-oxazolindine of the formula ##STR4## and heating the 2-methylene-3-(3-methyl-2-butenyl)-oxazolidine to produce a 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazoline.

Abstract: There is provided a new class of crown ethers characterized by an --OH functional group attached to a carbon atom in the heterocyclic ether ring portion and derivatives thereof. A novel process for making such crown ethers is also provided which is characterized by reacting a bisphenol ether with an epihalohydrin to effect ring closure and provide the appendant --OH group.These products are especially useful as complexing agents.

Abstract: A process for preparing substituted or unsubstituted benzoxazoline compound by reacting ammonia, a cycloalkanone and oxygen in the presence of metal cations.

Abstract: A process comprising reacting a 2-methyloxazoline of the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each independently is hydrogen, alkyl, aralkyl, optionally substituted aryl or two of them together form a ring,with a 3-methyl-2-buten-1-yl derivative of the formula ##STR2## in which X is halide, sulphonate or phosphate, thereby to produce a 2-methyl-3-(3-methyl-2-butenyl)-2-oxazolinium salt of the formula ##STR3## reacting the oxazolinium salt with an alcoholate of the formulaR.sup.5 --O--M (V)in whichM is one equivalent of an alkali metal or alkaline earth metal cation,to produce an oxazolidine of the formula ##STR4## pyrolyzing the oxazolidine to produce a 2-methylene-3-(3-methyl-2-butenyl)-oxazolidine of the formula ##STR5## and heating the 2-methylene-3-(3-methyl-2-butenyl)-oxazolidine to produce a 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazoline of the formula ##STR6## The compounds (II), (III) and (IV) are new.

Abstract: Compounds of the formula I ##STR1## wherein at least one of the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is C.sub.1 -C.sub.4 alkyl and each of the others independently is hydrogen or C.sub.1 -C.sub.4 alkyl, or, if R.sub.1 and R.sub.3 are both hydrogen, R.sub.2 and R.sub.4 can form a C.sub.2 -C.sub.4 alkylene bridge in which one CH.sub.2 member can be replaced by oxygen. These compounds possess valuable microbicidal properties, and they can be used in actual practice by themselves, or in the form of pesticidal compositions, especially for protecting cultivated plants from attack by fungus. The compounds of formula I have both a residual-protective and a systemic action.

Abstract: Fungicidally active novel spiro derivatives of 3-(3,5-dihalogenophenyl)-oxazolidine-2-thion-4-ones of the formula ##STR1## in which X and Y each independently is halogen, andn is 2 or 3,are produced by reacting an .alpha.-hydroxy-cycloalkylcarboxylic acid or acid ester of the formula ##STR2## in which R is hydrogen or alkyl with 1 to 4 carbon atoms,(a) with an isothiocyanate of the formula ##STR3## or (b) with an aniline of the formula ##STR4## in the presence of a diluent, and then cyclizing the .alpha.

Abstract: A process comprising reacting a 2-methyloxazoline of the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each indpendently is hydrogen, alkyl, aralkyl, optionally substituted aryl or two of them together form a ring,with a 3-methyl-2-buten-1-yl derivative of the formula ##STR2## in which X is halide, sulphonate or phosphate,thereby to produce a 2-methyl-3-(3-methyl-2-butenyl)-2-oxazolinium salt of the formula ##STR3## reacting the oxazolinium salt with an alcoholate of the formulaR.sup.5 --O--M (V)in whichM is a one equivalent of an alkali metal or alkaline earth metal cation,to produce an oxazolidine of the formula ##STR4## pyrolyzing the oxazolidine to produce a 2-methylene-3-(3-methyl-2-butenyl)-oxazolidine of the formula and heating the 2-methylene-3-(3-methyl-2-butenyl)-oxazolidine to produce a 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazoline of the formula ##STR5## The compounds (II), (III) and (IV) are new.

Abstract: Novel 3-oxoscirpen-4.beta.,15-diol esters and derivatives thereof are provided for use as antitumor agents. Also provided are processes for producing the above compounds and methods for using them to inhibit malignant tumors in mammals.

Abstract: Substituted spiro-derivatives of 3-(3,5-dihalogenophenyl)-oxazolidine-2,4-diones(thione-ones) of the formula ##STR1## in which A is oxygen or sulphur,X and Y each independently is halogen,Z each independently is alkyl or a fused cycloalkane or cycloalkene ring,m is 1, 2, 3 or 4, andn is 2 or 3.which possess fungicidal properties.

Abstract: Novel spiro-oxazolidindiones useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed.

Abstract: Metal salts of hydrocarbyl oxazoline phosphorodithioic acids are novel compounds effective for reducing friction and wear when added to a lubricant.

Abstract: Phosphosulfurized hydrocarbyl oxazoline reacted with nitrogen-containing compounds and certain olefins are novel compounds effective for reducing friction and wear when added to a lubricant.

Abstract: Metal salts of hydrocarbyl oxazoline phosphorodithioic acids are novel compounds effective for reducing friction and wear when added to a lubricant.

Abstract: Metal salts of phosphosulfurized hydrocarbyl oxazoline phosphorodithioic acids are novel compounds effective for reducing friction and wear when added to a lubricant.

Abstract: Cultivation of Streptomyces chartreusis NRRL 11407 in the presence of antibiotic A23187 methyl ester produces 16-hydroxy A23187 methyl ester, 16-hydroxy-N-demethyl A23187 methyl ester, and N-demethyl A23187 methyl ester. Hydrolysis of the products affords the corresponding free acids which form dimeric complexes with divalent cations.

Abstract: This invention relates to novel compounds of the general formula ##STR1## Representative compounds within the scope of the invention are ##STR2## The compounds are disclosed as being useful for treating symptoms and signs of cardiac failure by stimulating the .beta.-receptors of the heart. Methods of treatment using these compounds are discussed.

Abstract: A process for the preparation of an indolenine of the general formula I ##STR1## where R, R.sup.1 and R.sup.2 are aliphatic radicals and R.sup.1 and R.sup.2 may also be linked and the ring A may be additionally substituted, wherein a compound of the formula II ##STR2## is heated in the presence of a Lewis acid and of a halide. The products are valuable starting compounds for the preparation of dyes.

Abstract: Iodo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with iodine monochloride, and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems and (2) useful chemical tools for removal of recovery of ions.

Abstract: Bromo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with pyridinium hydrobromide perbromide and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems, and (2) useful chemical tools for removal and recovery of ions.

Abstract: Novel spiro-oxazolidinediones useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed.

Abstract: Halo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with an N-halo-type halogenating agent, and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems, (2) useful chemical tools for removal and recovery of ions, and (3) potential cardiotonic agents.

Abstract: Novel 2-(2,2-dihalogenovinyl)-3,3-dimethylcyclopropanecarboxylic acid derivatives of the formula ##STR1## e.g. amides, thioamides, oxazolines, amidoximes and hydroxamic acids, are produced by reacting the new compounds ##STR2## with a base in the presence of a diluent.

Abstract: Novel spiro-oxazolidindiones useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed.

Abstract: Spiro derivatives of 3-(3,5-dihalogenophenyl)-oxazolidine-2,4-diones of the formula ##STR1## in which X and Y each independently is halogen, andn is 2 or 3,which possess fungicidal properties.

Abstract: A polyparabanic acid derivative having a recurrent structural unit of the formula ##STR1## wherein X is O or S; each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, when taken separately is hydrogen or an aliphatic, aromatic or aliphatic-aromatic group; R.sup.1 and R.sup.2 when taken together complete a cycloaliphatic ring and R.sup.3 and R.sup.4 when taken together complete a cycloaliphatic ring and each of R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, is an aliphatic, aromatic or aliphatic-aromatic residue of an organic isocyanate after removal of at least one isocyanate group and method of producing same by reacting a compound of the formula ##STR2## with at least one organic isocyanate having at least two isocyanate groups at a temperature of from -20.degree. to 400.degree. C.

Abstract: This invention deals with chemical intermediates having the formula ##STR1## wherein R.sub.1 and R.sub.2 together with the carbon atom to which they are attached form a single hetero atom member selected from the group consisting of a five-to seven-membered heterocycle containing one hetero-N-atom and a N-substituted five-to seven-membered heterocycle containing an hetero-N-atom whose substituent is C.sub.1 -C.sub.2 alkyl. These compounds are useful in the synthesis of compounds having a variety of uses as pharmaceuticals.

Abstract: The present invention relates to a new organic heterocyclic isocyanate which is the reaction product of an organic diisocyanate and an amino or hydroxy nitrile. The invention also relates to a process of producing such isocyanates by reacting an excess of the diisocyanate with the nitrile under conditions under which the nitrile will not decompose and then maintaining the reaction mixture at an elevated temperature until the isocyanate nitrile adduct cyclizes. The reaction may be carried out in the presence of a catalyst for isocyanate addition reactions. Additionally, the invention relates to a process for the production of polyurethane by the reaction of the heterocyclic isocyanates with compounds carrying at least two isocyanate reactive hydrogen atoms per molecule.